Key Insights

Highlights

Treatment Research

8 treatments under study, led by Defactinib

Research Leaders

7 sponsors active, led by Verastem, Inc.

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
Phase 1 (1)
Phase 2 (1)
Phase 3 (1)

Trial Status

Active Not Recruiting2
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT06072781Phase 3RecruitingPrimary

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT03875820Phase 1Active Not Recruiting

Phase I Trial of Defactinib and VS-6766.

NCT06682572Phase 2Active Not RecruitingPrimary

A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Showing all 3 trials

Research Network

Common Treatments

  • Defactinib2
  • Anastrozole1
  • Avutometinib Vs6766 Defactinib Vs60631
  • Liposomal Doxorubicin1
  • Paclitaxel1

Active Sponsors

  • Verastem, Inc.3
  • GOG Foundation1
  • Institute of Cancer Research, United Kingdom1
  • Korean Gynecologic Oncology Group1
  • Japanese Gynecologic Oncology Group1

Top Investigators

Related Conditions

  • Ovarian Cancer1
  • Endometrioid Carcinoma1
  • Nsclc1
  • Pancreatic Cancer1
  • Recurrent Lowgrade Serous Ovarian Cancer Lgsoc1

Activity Timeline